Mumps virus, a member of the Paramyxoviridae family, causes a contagious viral infection chiefly affecting the salivary glands. The enzyme-linked immunosorbent assay (ELISA) for Mumps virus antibodies is a cornerstone for serological diagnosis, epidemiological surveys, and vaccine efficacy assessments.
Test Principle
Mumps virus ELISA kits detect IgG and/or IgM antibodies specific to Mumps virus antigens, frequently using recombinant nucleoproteins or whole-virus antigen coated on microtiter plates. Patient serum or plasma is added to antigen-coated wells, allowing antigen-antibody binding. After washing, enzyme-labeled anti-human IgG or IgM secondary antibodies are added, followed by a chromogenic substrate such as tetramethylbenzidine (TMB). The resulting colorimetric change, measured spectrophotometrically, correlates with antibody concentration, enabling qualitative or quantitative analysis.
Clinical and Epidemiological Applications
- Acute Diagnosis: IgM antibody detection supports diagnosis in symptomatic patients.
- Immune Status Monitoring: IgG ELISA determines seroconversion post-vaccination and population immunity.
- Surveillance: ELISA-based serosurveys guide public health interventions by elucidating immunity gaps.
- Complication Diagnosis: Cerebrospinal fluid ELISA aids in identifying mumps virus involvement in meningitis.
Mumps virus ELISA kits are essential tools for accurate serological diagnosis, immune monitoring, and epidemiological surveillance. Advances in antigen design and assay formats continue to enhance their diagnostic performance and clinical relevance.